Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy
Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy have?
Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy has 21 citations in the OpenAlex counts ScholarIQ stores.
When was Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy published?
Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy has 2022 year in the ScholarIQ index.
What is the open-access status of Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy?
Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy has gold oa status in the ScholarIQ index.
What is the DOI of Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy?
The DOI for Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy is on the source record.
What is the PMID of Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy?
The PMID for Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy is on the source record.
What is the OpenAlex record for Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy?
The OpenAlex for Effectiveness of ustekinumab in patients with refractory Crohn’s disease: a multicentre real-life study in Italy is on the source record.